1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 | Licensing Program Analyst (LPA) JoAnn Rosales conducted a Case Management - Deficiencies visit at the facility. LPA met with staff Matteo DiGrigoli who is authorized to review and sign reports.
During facility tour on 10/14/2021 starting at 11:35 am with staff Ashley Villareal LPA observed wound cleanser, wound gel, wound dressing, laundry detergent, cough suppressant, levetiracetam tablets, pantoprazole tablets, ibuprofen, sertraline tablets, januvia tablets, finasteride tablets, aspirin, mirtazapine tablets, tylenol, melatonin, vitamin D3, miralax, quetiapine tablets, gaviscon antacid, polyethylene glycol, laxaclear, albuterol inhaler, clopidogrel tablets, RA col-rite capsules, atorvastatin tablets, docusate sodium soft gels in an unlocked room #119 in memory care accessible to residents. During facility tour on 10/14/21 at 12:36 pm with staff DiGrigoli LPA observed staff #1 (S1) working and not associated to the facility. Staff stated that they have been working at the facility for 1 to 2 months. LPA verified through Guardian that S1 is fingerprint cleared and not associated to the facility. Staff DiGrigoli stated that they do not have any documentation of S1 being associated to the facility.
Pursuant to Title 22 Division 6 Chapter 8 of the CA Code of Regulations, the following deficiencies were cited (refer to LIC 809-D).
Civil penalties issued in the amount of $750.00.
Exit interview was conducted, today's reports, civil penalties and appeal rights were reviewed and emailed to the Operations Manager |